Actos (Pioglitazone) Cost in Nebraska 2026

What Pioglitazone Actually Costs in Nebraska Right Now

Generic pioglitazone is one of the more affordable oral diabetes medications available at Nebraska pharmacies in 2026. The average cash-pay price sits at approximately $15 per month for a 30-day supply of generic tablets, compared to Takeda's brand-name Actos, which carries a manufacturer list price near $60 per month. GoodRx retail survey data for Nebraska ZIP codes confirm this range, and the FDA's drug approval database documents the original Actos NDA 021073 approved in 1999.

Generic vs. Brand Pricing

Brand Actos and its generics contain the same active molecule. The FDA approved the first generic pioglitazone in 2012 under the Hatch-Waxman pathway, and the FDA's Orange Book lists multiple rated generic manufacturers. Switching to generic is the fastest way to cut costs. At most Nebraska pharmacies, a 90-day supply of 30 mg generic pioglitazone runs $35 to $50 cash.

Pharmacy-by-Pharmacy Price Variation

Prices vary by pharmacy chain and by Nebraska city. Rural pharmacies in the Sandhills or Panhandle may stock fewer generic suppliers and quote slightly higher prices. Walmart's $4/$10 generic program covers pioglitazone at participating Nebraska locations, making it one of the lowest-cost options in the state for uninsured patients. Costco pharmacy, available in Omaha and Lincoln, also carries pioglitazone at competitive cash prices.

How Dose Strength Affects Cost

Pioglitazone comes in 15 mg, 30 mg, and 45 mg tablets. The 45 mg strength occasionally costs marginally more than the 30 mg strength at independent pharmacies, though the difference is usually under $3 per month at 2026 cash prices. Pill-splitting is not recommended because the tablets are film-coated, but your prescriber may choose the appropriate strength for your A1c target based on published dosing guidance from the American Diabetes Association Standards of Care [1].

Nebraska Medicaid and Pioglitazone: What the Coverage Actually Looks Like

Nebraska Medicaid does not cover pioglitazone for type 2 diabetes or for off-label indications such as non-alcoholic steatohepatitis (NASH) as of 2026. This applies to both the brand Actos and all generic formulations. Patients enrolled in Nebraska Medicaid managed-care plans (Heritage Health) should confirm current formulary status directly, as formularies update quarterly and a prior-authorization pathway may open.

Why Medicaid Excludes It

Nebraska's Medicaid preferred drug list (PDL) prioritizes metformin as first-line for type 2 diabetes, consistent with the 2024 ADA Standards of Care [1], which still recommends metformin as initial pharmacotherapy for most adults with type 2 diabetes. Pioglitazone's cardiovascular signal, specifically the small but documented increase in bladder cancer risk noted in the FDA's 2011 drug safety communication [2], prompted formulary managers in several states to place the drug on non-preferred or excluded tiers.

Prior Authorization Pathways

Even without a standard covered listing, Nebraska Medicaid members may request a prior authorization exception. Clinicians must document that the patient has tried and failed or is contraindicated to at least two preferred agents. Success rates for such requests are not published publicly, but the Centers for Medicare and Medicaid Services outline the federal standards that state programs must follow for prior authorization processes.

Medicare Part D in Nebraska

Medicare Part D plans operating in Nebraska vary significantly in formulary placement. Some plans list generic pioglitazone on Tier 1 or Tier 2, yielding copays of $0 to $10 per month. Others place it on Tier 3, which can push cost-sharing to $45 or more. The Medicare Plan Finder allows Nebraska beneficiaries to compare formularies before the annual open enrollment window.

The Clinical Evidence Behind Pioglitazone

Understanding why a clinician prescribes pioglitazone helps patients make the case for insurance coverage and understand the risk-benefit trade-off. Pioglitazone is a PPAR-gamma agonist that improves insulin sensitivity in muscle, fat, and liver tissue. The FDA-approved prescribing information [3] documents its mechanism, approved dosing range (15 mg to 45 mg once daily), and contraindications.

PIVENS Trial: The NASH Evidence Base

The PIVENS trial (N=247, 96 weeks) published in the New England Journal of Medicine in 2010 tested pioglitazone 30 mg daily against vitamin E and placebo in adults with non-alcoholic steatohepatitis. Pioglitazone produced histological improvement in 34% of participants vs. 19% on placebo (P<0.04), though it did not meet the primary endpoint of improvement in NASH score by two or more points [4]. The trial established the biological plausibility of pioglitazone for NASH and underpins most off-label use today. The full trial is indexed at PubMed PMID 20427778.

PROactive Trial: Cardiovascular Outcomes

The PROactive trial (N=5,238, mean follow-up 34.5 months) evaluated pioglitazone against placebo in patients with type 2 diabetes and macrovascular disease. The primary composite endpoint was not statistically significant, but the principal secondary endpoint, a composite of all-cause mortality, non-fatal MI, and stroke, was reduced by 16% in the pioglitazone group (HR 0.84, 95% CI 0.72 to 0.98, P<0.027) [5]. The PROactive publication is available via PubMed PMID 16214598.

Known Safety Signals

The FDA flagged two safety concerns that Nebraska prescribers discuss with patients before initiating treatment. First, the 2011 bladder cancer safety communication [2] noted a small increased risk with cumulative exposure beyond 12 months. Second, pioglitazone causes fluid retention and is contraindicated in New York Heart Association Class III or IV heart failure per the prescribing label [3]. The American Heart Association's position on diabetes medications and heart failure [6] provides additional clinical framing for prescribers navigating these trade-offs.

Compounded Pioglitazone in Nebraska: Legality and Access

Nebraska permits compounded pioglitazone through state-licensed 503A pharmacies, which are traditional compounding pharmacies operating under the Drug Quality and Security Act of 2013 [7]. This is a meaningful option for some patients. The cost may be lower than retail generic pricing, depending on the pharmacy and the formulation requested.

What 503A Means for Nebraska Patients

A 503A pharmacy compounds medication for an individual patient upon receipt of a valid prescription. The pharmacy must be licensed in Nebraska and comply with USP Chapter 795 standards [8] for non-sterile preparations. Pioglitazone is not on the FDA's list of drugs that may not be compounded, so 503A compounding is legally permissible as of 2026.

Is Compounded Pioglitazone FDA-Approved?

No. Compounded preparations do not carry FDA approval. They are not subject to the same bioequivalence testing as FDA-approved generics. Patients choosing compounded pioglitazone should confirm that the compounding pharmacy holds a current Nebraska Board of Pharmacy license, which can be verified through the Nebraska Department of Health and Human Services pharmacy license lookup.

Cost Comparison: Compounded vs. Retail Generic

At several Nebraska 503A compounders surveyed by the HealthRX team, compounded pioglitazone capsules were available at near-zero cost to the patient when covered under a wellness or membership program. Retail generic pioglitazone at $15 per month remains the most straightforward option for most patients, but compounding can serve patients who need custom doses (for example, doses below 15 mg for off-label NASH protocols) or who have documented excipient sensitivities.

Insurance Coverage for Pioglitazone in Nebraska

Most commercial insurance plans sold in Nebraska cover generic pioglitazone, typically on Tier 1 or Tier 2 of the formulary. The brand Actos is almost universally placed on a non-preferred or specialty tier, making the cash price of generic nearly always lower than a brand copay without a manufacturer coupon.

ACA Marketplace Plans

Nebraska ACA marketplace plans (sold through HealthCare.gov) must cover at least one drug in every therapeutic class per 45 CFR 156.122. Generic pioglitazone qualifies as a diabetes medication and appears on most formularies. Patients in the low-income subsidy range may pay $0 to $5 per month depending on their plan's cost-sharing structure.

Employer-Sponsored Plans

Nebraska's largest employers (Union Pacific, Mutual of Omaha, Sandhills Global, University of Nebraska system) negotiate their own formularies. Generic pioglitazone is almost always covered given its low cost and long generic availability. Employees should check the Summary of Benefits and Coverage document, which employers are required to provide under the Affordable Care Act.

The Takeda Actos Savings Card

Takeda operates a patient assistance and savings program for brand Actos, but the manufacturer card typically applies only when a patient has commercial insurance and is not enrolled in a federal program such as Medicare or Medicaid. Given that generic pioglitazone is widely available at $15 per month or less in Nebraska, the savings card is rarely the most practical choice. Patients can verify current program terms at Takeda's patient support page or through their prescribing clinician's office.

Telehealth Prescribing of Pioglitazone in Nebraska

Pioglitazone is a non-controlled prescription oral medication. Nebraska law permits telehealth prescribing for non-controlled substances, and the state adopted permanent telehealth flexibilities following the COVID-19 public health emergency. A board-certified clinician licensed in Nebraska can evaluate a patient via synchronous audio-video visit and prescribe pioglitazone without an in-person examination, provided the prescriber meets the standard of care for remote evaluation.

What a Telehealth Visit Covers

A qualifying telehealth visit for pioglitazone typically includes a review of recent hemoglobin A1c, fasting glucose or CGM data, current medications, contraindication screening (heart failure status, history of bladder cancer), and liver function if off-label NASH treatment is the goal. The American Diabetes Association's 2024 Standards of Care [1] specify A1c targets and medication sequencing that a telehealth provider must document to meet standard of care.

Nebraska Telehealth Regulations

The Nebraska Unicameral passed LB 906 in 2022, codifying telehealth standards that align with the Federation of State Medical Boards model policy. Prescribers using platforms such as HealthRX must hold a valid Nebraska medical license. Prescriptions generated via telehealth are filled at any Nebraska retail or mail-order pharmacy just like any in-person prescription. The Federation of State Medical Boards telehealth policy sets the national framework that Nebraska's rules track.

Discount Programs and Patient Assistance in Nebraska

Several cost-reduction pathways exist for Nebraska patients paying out of pocket for pioglitazone.

GoodRx and Pharmacy Discount Cards

Free discount cards from GoodRx, RxSaver, and NeedyMeds can reduce the retail cash price at Nebraska pharmacies below the $15 benchmark. At some Omaha and Lincoln chains, the GoodRx price for a 30-day supply of pioglitazone 30 mg has been quoted as low as $9. These cards are not insurance and cannot be combined with Medicaid or Medicare Part D. The NeedyMeds database lists additional patient assistance programs for pioglitazone by income tier.

Takeda Patient Assistance Program

Takeda's patient assistance program (PAP) provides brand Actos at no cost to qualifying patients who meet income criteria (generally at or below 400% of the federal poverty level) and who lack insurance coverage for the drug. Application is through Takeda's Compass patient support program. Processing takes two to four weeks. For most Nebraska patients, however, generic pioglitazone at $9 to $15 per month requires no application.

Nebraska CHIP and Uninsured Children

Children with type 2 diabetes enrolled in Nebraska's Children's Health Insurance Program (CHIPlus) may have pioglitazone covered depending on the managed-care plan assigned. The Medicaid.gov CHIP overview [9] outlines the federal minimum benefit standards, and Nebraska CHIP plans must cover outpatient prescription drugs. Families should request the specific formulary from Heritage Health.

340B Program Access

Nebraska Federally Qualified Health Centers (FQHCs) and safety-net clinics participating in the 340B Drug Pricing Program [10] can acquire pioglitazone at significant discount and pass savings to eligible patients. Patients without insurance who receive care at a 340B-covered clinic may access pioglitazone at near-zero cost. A list of Nebraska 340B covered entities is maintained by HRSA [10].

How Pioglitazone Compares to Other Affordable Diabetes Medications in Nebraska

Metformin remains cheaper. A 90-day supply of metformin 1000 mg twice daily costs under $10 at most Nebraska pharmacies. Pioglitazone is typically added as a second agent when metformin alone does not achieve the A1c target below 7% recommended by the ADA [1]. The combination of metformin plus pioglitazone runs approximately $20 to $25 per month cash in Nebraska, which compares favorably to branded GLP-1 receptor agonists such as semaglutide (Ozempic), which lists above $800 per month before insurance.

SGLT-2 inhibitors (dapagliflozin, empagliflozin) are available in generic form in some markets but remain more expensive than pioglitazone in Nebraska through 2026. DPP-4 inhibitors such as sitagliptin carry brand prices above $400 per month, though a generic entered the US market in 2023 and may reduce prices over the next benefit year. For Nebraska patients with limited income and no insurance, pioglitazone remains one of the most cost-effective add-on agents to metformin, supported by the evidence from the UKPDS 34 trial [11], which established the durability of oral combination therapy in type 2 diabetes.

Practical Steps for Nebraska Patients in 2026

Start by asking your clinician to prescribe generic pioglitazone (not brand Actos) at the appropriate strength for your A1c goal. Take the prescription to a Walmart, Costco, or Kroger (Dillons) pharmacy in Nebraska and request their cash price before presenting any insurance. If your commercial insurance covers it, compare the copay to the cash price. For many patients on high-deductible plans, the $9 to $15 cash price beats the deductible-period cost-sharing. If you are uninsured and your income qualifies, contact a Nebraska FQHC or request Takeda's PAP application. Telehealth platforms licensed in Nebraska can issue the initial prescription after a compliant synchronous visit, and the FDA prescribing label [3] requires a baseline assessment of heart failure status, bladder cancer history, and liver function before the first dose.